Vancouver Centre
 

        
                       Wednesday, December 17, 2014 <Return to Open Clinical Trials> 

Listed below are the current open Medical Oncology Clinical Trials at BCCA - Vancouver Centre (VC):

If you are interested in more information about a particular trial, please talk with your treating physician first, and they may contact this centre for further information if necessary.

TUMOUR GROUP/SITE TRIAL TITLE DATE OPENED

BREAST

 
A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HER2-negative breast cancer.
BCCA CODE:  BRTA2201
July 2014
  A randomized multicenter, open-label, phase III trial comparing trastuzumab plus pertuzumab plus taxane following anthracyclines versus trastuzumab emtansine plus pertuzumab following anthracyclines as adjuvant therapy in patients with operable HER2 positive primary breast cancer.
BCCA CODE:  BRTKAITLIN
May 2014
  A phase II, single arm, open label, multicenter study of the clinical activity and safety of Enzalutamide in patients with advanced, androgen receptor-positive, triple-negative breast cancer
BCCA CODE:  BRTENZA
January 2014
  A randomized, multicenter, open-label phase III study to evaluate the efficacy & safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy for subjects with HER2-positive primary breast cancer who have residual tumour present pathologically in the breast or axillary lymph nodes following pre-operative therapy
BCCA CODE:  BRT27938
October 2013
  A randomized phase II study of reolysin for patients receiving standard weekly paclitaxel therapy as therapy for advanced/metastatic breast cancer
BCCA CODE:  BRIND213
February 2013
   A phase III, randomized clinical trial of trial of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-3 positive nodes, hormone receptor-positive and HER2-negative breast cancer with recurrence score (RS) of 25 or less.
BCCA CODE: BRMAC15
December 2011
  A phase II prospective trial correlating progression free survival with CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen.
BCCA CODE: BRECOG3108 (on HOLD)
September 2011
  A phase II clinical trial to evaluate 18F-Fluorestradiol positron emission tomography / computerized tomography (PET/CT) guided fulvestrant therapy for patients with rosarian or metastatic breast cancer
BCCA CODE: BRTFULCT
November 2010

Back to Top

CENTRAL NERVOUS SYSTEM (CNS)
   

Back to Top

GASTROINTESTINAL (GI) A double blind, randomized, placebo controlled phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.
BCCA CODE: GITLUME1
November 2014
  A phase Ib/II, open-label study of LJM716 in combination with BYL719 compared to taxane or irinotecan in patients with previously treated esophageal squamous cell carcinoma.
BCCA CODE: GITX2103
September 2014
  A phase II/III of neoadjuvant FOLFOX with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total mesorectal excision.
BCCA CODE: GICRC7
August 2013
  A phase III, multicenter, randomized, double-blind, placebo controlled study of rilotumumab (AMG 102) with epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in advanced MET-positive gastric or gastroesophageal junction adenocarcinoma.
BCCA CODE: GIT00622
June 2013
  Multicentre randomized phase III study comparing 6-month adjuvant chemotherapy with gemcitabine versus 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (mFolfirinox) in patients with resected pancreatic adenocarcinoma
BCCA CODE: GIPA6
March 2013
  A randomized, multicentre, adaptive phase II/III study to evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) versus taxane (docetaxel or paclitaxel) in patients with previsouly treated locally advanced or metastatic Her2-positive gastric cancer, including adenocarcinoma of the gastroesophageal junction
BCCA CODE: GITGATSBY 
February 2013
  A randomized phase II study of reolysin in combination with folfax6/bevacizumab or folfax6/bevacizumab alone in patients with meetastatic colorectal cancer
BCCA CODE: GIIND210
January 2013
  A Phase I/II Study of the PI3Kinase Inhibitor BKM120 given in combination with Panitumumab inpatients with metatastic or advanced RAS-Wild Type Colorectal Cancer.
BCCA CODE: GIIND208
August 2012
  A phase II single arm study of AUY922 in patients with metastatic pancreatic adenocarcinoma who are resistant to first line chemotherapy.
BCCA CODE: GIDDP922
April 2012
  ...A multicentre, opel-label phase II study of irinotecan, capecitabine (Xeloda®) and oxaliplatin (IXO) as first line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
BCCA CODE: GITIXOG001
April 2012
  A phase III trial of 6 versus 12 treatments of adjuvant FOLFOX plus Celecoxib or placebo for patients with resected stage lll colon cancer.
BCCA CODE: GICRC6
September 2011
  A phase lll randomized study of Sorafenib (IND 69896, NSC 724772) plus Doxorubicin versus Sorfenib in patients with advanced hepatocellular carcinoma (HCC)
BCCA CODE: GIHEC.1 
May 2011
  A phase lll study of the impact of a physical activity program on disease-free survival in patients with high risk stage ll or stage lll colon cancer: a randomized controlled trial (challenge)
BCCA CODE: GICO21
July 2009

Back to top

GENTOURINARY (GU) - Bladder

A multicentre randomized phase II trial comparing nab-paclitaxel in patients with advanced urothelial cancer progressing on or after a platinum containing regimen
BCCA CODE: GUTBL12

September 2014
 

A phase I study of safety and pharmacokinetics of escalating doses of AGS15E given as monotherapy in subjects with metastatic urothelial cancer
BCCA CODE: GUTAGS15E

December 2013
GENTOURINARY (GU) - Kidney A randomized phase II study of afinitor (everolimus) versus sutent (sunitinib) in patients with metastatic non-clear cell renal cell carcinoma
BCCA CODE:  GUTCA20916
August 2012
  A Phase II, Multi-centre, study of the efficacy and safety of Sunitinib given on an individualized schedule as first line therapy for metatastic renal cell cancer.
BCCA CODE: GUTOZM042
October
2012
GENTOURINARY (GU) - Prostate A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednosolone in treatment of asymptomatic or mildly symptomatic chemotherapy-native subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC).
BCCA CODE: GUTBAY8223
December 2014
  A phase II randomized, multi-center study of cabazitaxel versus abiraterone or enzalutamide in poor prognosis-metastatic castration-resistant prostate cancer
BCCA CODE: GUTOZM054
November 2014
  A phase II randomized, open-label, parallel group study to evaluate the safety and efficacy of the oral GnRH antagonist TAK-385, together with a Leuprorelin observational cohort, in patients with prostate cancer
BCCA CODE: GUTTAK385
October 2014
  A randomized phase II study of sequencing abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
BCCA CODE: GUTABIENZA
September 2014
  A drug-drug interaction, safety and efficacy study with JNJ-56021927 (ARN-509) and abiraterone acetate in subjects with metastatic castration-resistant prostate cancer
BCCA CODE: GUTARN509
September 2014
  Radiologically guided biopsies of metastatic castration resistant prostate cancer to identify adaptive mechanisms of resistance
BCCA CODE: GUT125519
November 2013
  A randomized phase II study evaluating OGX-427 in patients with metastatic castrate-resistant prostate cancer who have PSA progression while receiving abiraterone
BCCA CODE: GUTPR02
January 2013
  A randomized phase II study of reolysin in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic castration resistant prostate cancer
BCCA CODE: GUIND209
November 2012
Back to top
GYNECOLOGY A phase II study of oral ENMD-2076 administered to patients with ovarian clear cell carcinomas
BCCA CODE: GO2076
July 2014
  A phase II, open-label study of Rucaparib in patients with platinum-sensitive, relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer
BCCA CODE: GOTARIEL2 (ON HOLD)
May 2014
  A phase III randomized double-blind trial of maintenance with Niraparib versus placebo in patients with platinum sensitive ovarian cancer
BCCA CODE: GOTNIRA
April 2014
  A multinational, randomized, open-label phase III study of MEK162 vs. physician's choice chemotherapy in patients with recurrent of persistent low-grade serous carcinomas of the ovary, fallopian tube or primary peritoneum
BCCA CODE: GOTMILO
March 2014
  A phase II study of ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma of either squamous cell or adenocarcinoma histologies
BCCA CODE: GOPHL085
March 2014
Back to top     
HEAD & NECK An open label, randomzied phase III clinical trials of Nivolumab vs Therapy of Investigator's Choice in recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck
BCCA CODE: HNT209141
October 2014
A phase IIB randomized, placebo controlled trial of pioglitazone for oral premalignant lesions: an inter-consortium collaborative study
BCCA CODE: HNINC07
May 2013
  A randomize, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients with stage III, IVa or IVb loco-regionaly advanced head and neck squamous cell carcinoma
BCCA CODE: HNTAFA
January 2012
Back to top                 
LUNG A phase III, open label, randomized study of AZD9291 versus platinum-based doublet chemotherapy for patients with locally advanced or metastatic non-small cell lung whose disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapy and whose tumours harbour a T790M mutation within the epidermal growth factor receptor gene (AURA3) 
BCCA CODE: LUTAURA3
November 2014
  A phase II, multicenter, single-arm study of MPDL3280A in patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer 
BCCA CODE: LUTBIRCH
May 2014
  A phase IB study of selumetinib in patients with previously treated or untreated advanced/metastatic NSCLC who are receiving standard chemotherapy regimens 
BCCA CODE: LUIND215
January 2014
  A randomized phase II study of reolysin in patients with previously treated advanced or metastatic, non small cell lung cancer receiving standard salvage therapy
BCCA CODE: LUIND211
March 2013
  Detection of Hypoxia and blood flow using PET and CT scans in patients with advanced non-small cell lung cancer receiving chemotherapy with or without bevacizumab: a pilot study.
BCCA CODE: LUTHYPOXIA
March 2012
Back to top
LYMPHOMA A randomized, double-blind, placebo-controlled phase III study of the Bruton's tyrosine kinase (BTK) inhibitor, PCI-32765 (ibrutinib), in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma.
BCCA CODE: LYTPHOENIX
March 2014
  A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib (GS-1101) in combination with Bendamustine and Rituzimab for previously treated indolent non-hodgkin lymphoma
BCCA CODE: LYTGS1101
December 2013
  A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma
BCCA CODE: LYLY15
September 2013
  A randomized, open-label, phase III trial of A+AVD versus ABVD as frontline therapy in patients with advanced classical hodgkin lymphoma
BCCA CODE: LYTC25003
May 2013
  A phase I/II clinical trial of the combination of brentuximab vedotin and bendamustine in patients with relapsed or refractory hodgkins lymphoma or anaplastic large cell lymphoma
BCCA CODE: LYT1100448
April 2013
  A randomized, double-blind, placebo-controlled, phase III study of bretuximab vedotin and CHP (A + CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas
BCCA CODE: LYT35014
March 2013
  A phase III, multicenter, open-label, randomized trial comparing the efficacy of GA101 (RO5072759) in combination with CHOP (G-CHOP) versus Rituximab and CHOP (R-CHOP) in previously untreated patients with CD20-positive diffuse large G-Cell Lymphoma (DLBCL)
BCCA CODE: LYTGOYA
April 2012
  A phase II trial tailoring first-line therapy for advanced stage diffuse large B-cell Non-Hodgkin's Lymphoma based on mid-treatment positron Emission Tomography (PET) scan results
BCCA CODE: LYPET
August 2006
Back to top
PHASE 1 A phase I, multi-center, open-label, study to investigate the safety, tolerability and pharmacokinetic of SLC-0111 in subjects with advanced solid tumours
BCCA CODE:P1TOZM055
November 2014
  A phase I trial of single agent trametinib (GSK1120212) in advanced cancer patients with dysfunction
BCCA CODE:P1PJC015
June 2014
  A phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of ascending doses of AZD5363 under adaptable dosing schedules in patients with advanced solid malignancies
BCCA CODE:P1TGIVEN
June 2014
  A phase IB open-label three-arm multi-center study to assess the safety and tolerability of PF-05212384 (PI13K/mTOR Inhibitor) in combination with other anti-tumor agents
BCCA CODE:P1TB21502
March 2014
  A phase I, multi-center, non-randomized, open label, parallel-group study evaluating the pharmacokinetics and safety of regorafenib (BAY 73-4506) in cancer subjects with severe renal impairment compared to a control group
BCCA CODE:P1TRAFENIB
November 2013
   Open-label dose-escalation trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of daily oral MGCD265 administered without interruption to subjects with advanced Malignancies.
Accrual ON HOLD as of 10 Dec 2013
BCCA CODE: P1TMG265
June 2008
Back to top
SARCOMA    
Back to top    
SKIN - MELANOMA A phase III, randomized, double-blind, placebo-controlled study of vemurafenib (RO5185426) adjuvant therapy in patients with surgically resected, cutaneous BRAF-Mutant melanoma at high risk for recurrence
BCCA CODE: SMTBRIM8
February 2013
Back to top
SYMPTOM MANAGEMENT    
Back to top
MULTIPLE
SITES
Utilization of genomic information to augment chemotherapy decision-making for people with incurable malignancies
BCCA CODE: no BCCA code available
July 2012
  A phase ll study of Sunitinib or Temsirolimus in patients with advanced rare tumours.
BCCA CODE: MOIND206
February 2012

 

SOURCE:Vancouver Centre (http://www.bccancer.bc.ca/ RES/ ClinTrials/ OpenTrials/ VC.htm).
Page printed:2014/12/20. Unofficial document if printed. Please refer to SOURCE for latest information.
Copyright ©2014 BC Cancer Agency. All Rights Reserved.